# EDGAR Filing Document

**Accession Number:** 0001595353
**File Stem:** 0001641172-25-025014
**Filing Date:** 2025-8
**Character Count:** 2228
**Document Hash:** 4c6f477e141e12e148005e85636309c5
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001641172-25-025014.hdr.sgml**: 20250919

**ACCESSION NUMBER**: 0001641172-25-025014

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250821

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Galmed Pharmaceuticals Ltd.
- **CENTRAL INDEX KEY:** 0001595353
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 981147233
- **STATE OF INCORPORATION:** L3
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** C/O MEITAR LAW OFFICES
- **STREET 2:** 16 ABBA HILLEL SILVER RD.
- **CITY:** RAMAT GAN
- **STATE:** L3
- **ZIP:** 5250608
- **BUSINESS PHONE:** 97236938448

**MAIL ADDRESS:**
- **STREET 1:** C/O MEITAR LAW OFFICES
- **STREET 2:** 16 ABBA HILLEL SILVER RD.
- **CITY:** RAMAT GAN
- **STATE:** L3
- **ZIP:** 5250608

Galmed Pharmaceuticals Ltd.

16 Abba Hillel Road

Ramat Gan, Israel 5250608

August 21, 2025

*<u>VIA EDGAR</u>*

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, DC 20549

RE: Galmed Pharmaceuticals Ltd. (CIK 0001595353) <br> <u>Registration Statement No. 333-289703 on Form F-1 (the "Registration Statement")</u>

Ladies and Gentlemen:

Galmed Pharmaceuticals Ltd. (the "<u>Registrant</u>") hereby requests acceleration of the effectiveness of the above-referenced Registration Statement pursuant to Rule 461 under the Securities Act of 1933, as amended (the "<u>Securities Act</u>"), so that it may become effective on August 21, 2025 at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable.

The undersigned respectfully requests that it be notified of the effectiveness of the Registration Statement by telephone call to our counsel, Greenberg Traurig, P.A., by calling Gary Emmanuel at +1 212 801 9337. The Company hereby authorizes Mr. Emmanuel to orally modify or withdraw this request for acceleration.

---

| | |
|:---|:---|
| Very truly yours, | Very truly yours, |
| Galmed Pharmaceuticals LTD. | Galmed Pharmaceuticals LTD. |
| By: | */s/ Allen Baharaff* |
|  | Allen Baharaff |
|  | Chief Executive Officer |

---